資源描述:
《吉西他濱聯(lián)合順鉑治療晚期乳腺癌療效觀察.pdf》由會員上傳分享,免費在線閱讀,更多相關內(nèi)容在應用文檔-天天文庫。
1、·3830·現(xiàn)代預防醫(yī)學2012年第39卷第15期ModernPreventiveMedicine,2012,Vo1.39,NO.15·兒少衛(wèi)生與婦幼保健·吉西他濱聯(lián)合順鉑治療晚期乳腺癌療效觀察周曉紅(安順市人民醫(yī)院腫瘤科,貴州安順561000)摘要:目的觀察吉西他濱聯(lián)合順鉑與長春瑞濱聯(lián)合順鉑治療晚期乳腺癌的臨床療效。方法將符合病例入選標準的乳腺癌患者160例患者采用隨機數(shù)字表法分為治療組和對照組,每組80例。觀察組予吉西他濱1000Ills/m2,靜脈滴注30min,dl,8;順鉑25mg/m2靜脈滴注,d3~5。對照組予長春瑞濱25mg/m2,dl,8,溶于生理鹽水100m
2、l中,快速靜脈滴注,順鉑25mg/m:靜脈滴注。d3-5。2組均以治療21d為1個周期。觀察2組患者的生活質(zhì)量、臨床療效及不良反應。結(jié)果CR觀察組為37.5O%。對照組為35.0o%,2組相比差異無統(tǒng)計學意義(P>0.05)??傆行视^察組為60.oo%.對照組為57.50%,2組相比較差異無統(tǒng)計學意義(P>0.05)。2組治療后均出現(xiàn)了不同程度的中性粒細胞減少、貧血、惡心嘔吐、脫發(fā)、發(fā)熱、肝功能損害、腎功能損害,但總體而言II—V級發(fā)生率兩組相比差異無統(tǒng)計學意義(P>0.05)。結(jié)論吉西他濱聯(lián)合順鉑與長春瑞濱聯(lián)合順鉑治療晚期乳腺癌的臨床療效相當,不良反應相當。關鍵詞:乳腺癌,
3、晚期;吉西他濱;長春瑞濱;順鉑中圖分類號:R737.9文獻標志碼:A文章編號:1003—8507(2012)15—3830—03ObservationofgemcitabinecombinedwithcisplatinintreatmentofadvancedbreastcancerZHOUXiao-hong.AnshunCityPeople’sHospital,All~hul$,Guizhou561000,ChinaAbstract:OBJECTIVEToobservetheefectofgemcitabineandcisplatinwitllChangchunvinorel
4、binecombinedwithcisplatinintreatmentofadvancedbreastcancer.METHODSWithaselectioncriteriaforpatientswithbreastcancerreportof160casestreatedwithrandomlyweredividedintotreatmentgroupandcontrolgroup,80casesineachgroup.Theobservationgrouptogemcitabinein1000mg/m,intravenousinfusionof30min,DL,8;25m
5、g/m2intravenousinfusionofcisplatin,d3-5.ThecontrolgroupreceivedChangchunvinorelbine25mg/m2,DL,8,dissolvedinsaline100ml,rapidintravenousinfusion,in-travenousinfusionofcisplatin25mg/m,d3-5.The2groupsweretreatedfor21dayswith1cycles.Obse~edpatients’qualityoflife,clinicaleficacyandadversereaction
6、intwogroups.RESULTSCRwas37.50%intreatmentgroup,controlgroupfor35%,2groupshadnosignificantdiference(尸>0.05).Thetotalefficiencyintreatmentgroupwas60%,57.50%incontrolgroup,therewasnosignificantdiference(P>0.05).Intwogroups,itshoweddiferentdegreesofneutropenia,anemia,nau·seaandvomiting,alopecia,
7、fever,liverdysfunction,renalimpairmentafterthetreatment,butoverall,IIVincidencerateoftwogroupsshowednostatisticalsign~cance(P>0.05).CONCLUSIONGemcitabinecombinedwitllcisplatinandChangchunvinorelbinecombinedwithcisplatinintreatmentofadvancedbreastca